Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA for patients living with tardive dyskinesia or Huntington disease chorea. With the approval and launch of CRENESSITY, we look forward to delivering the first new treatment for the congenital adrenal hyperplasia community in over 70 years, transforming the standard of care for patients,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine (NBIX) Biosciences. “With a rapidly advancing and growing pipeline and a strong financial profile, we are well positioned to build a leading neuroscience company.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $184 from $182 at BofA
- Neurocrine price target raised to $185 from $170 at Morgan Stanley
- NBIX Upcoming Earnings Report: What to Expect?
- Neurocrine price target raised to $176 from $162 at UBS
- Neurocrine initiates Phase 3 registrational program for osavampator in MDD